dipyridamole has been researched along with Bladder Cancer in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was performed to investigate the capability of gemcitabine and pemetrexed to synergistically interact with respect to cytotoxicity and apoptosis in T24 and J82 bladder cancer cells, and to establish a correlation between drug activity and gene expression of selected genes in tumour samples." | 9.12 | In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. ( Curigliano, G; Danesi, R; De Braud, F; De Cobelli, O; Del Tacca, M; Giovannetti, E; Mey, V; Nannizzi, S; Pece, S; Verweij, F, 2006) |
| "The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model." | 7.68 | Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. ( Donaldson, JT; Keane, TE; Norwood, DL; Poulton, SH; Rosner, G; Walther, PJ, 1990) |
| "The present study was performed to investigate the capability of gemcitabine and pemetrexed to synergistically interact with respect to cytotoxicity and apoptosis in T24 and J82 bladder cancer cells, and to establish a correlation between drug activity and gene expression of selected genes in tumour samples." | 5.12 | In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. ( Curigliano, G; Danesi, R; De Braud, F; De Cobelli, O; Del Tacca, M; Giovannetti, E; Mey, V; Nannizzi, S; Pece, S; Verweij, F, 2006) |
| "The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model." | 3.68 | Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. ( Donaldson, JT; Keane, TE; Norwood, DL; Poulton, SH; Rosner, G; Walther, PJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mey, V | 1 |
| Giovannetti, E | 1 |
| De Braud, F | 1 |
| Nannizzi, S | 1 |
| Curigliano, G | 1 |
| Verweij, F | 1 |
| De Cobelli, O | 1 |
| Pece, S | 1 |
| Del Tacca, M | 1 |
| Danesi, R | 1 |
| Witjes, JA | 1 |
| vd Meijden, AP | 1 |
| Doesburg, W | 1 |
| Debruyne, FM | 1 |
| Keane, TE | 2 |
| Rosner, GL | 1 |
| Gingrich, JR | 1 |
| Poulton, SH | 2 |
| Walther, PJ | 2 |
| Rosner, G | 1 |
| Donaldson, JT | 1 |
| Norwood, DL | 1 |
1 trial available for dipyridamole and Bladder Cancer
| Article | Year |
|---|---|
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis | 2006 |
3 other studies available for dipyridamole and Bladder Cancer
| Article | Year |
|---|---|
Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group.
Topics: Administration, Intravesical; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; BCG | 1993 |
The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cisplatin; Dipyridamole; Disease | 1991 |
Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Di | 1990 |